[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products

Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymphoma),Tecentriq (advanced rare sarcoma) andActemra/RoActemra (COVID-19)US priority review ofglofitamab (aggressive form of blood cancer)Positive phase III data forVabysmo (serious retinal vascular condition) and forTecentriq plusAvastin (early-stage liver cancer)Priority review forcrovalimab (rare blood disease) in ChinaNew study proves high medical value ofElecsys NT-proBNP heart testUS approval forAlzheimer ’s tests; US Emergency Use Authorization formpox virus testCore earnings per share rise by 5% (+2% in CHF)IFRS net incomeamounts to CHF 13.5 billion (-6%; -9% in CHF)Board proposesdividend increase to CHF 9.50. If approved by shareholders, this would be the 36th consecutive dividend increase.Outlook for 2023Due to the sharp decline in sales of COVID-19 products of roughly CHF 5 billion, Roche expects a decrease inGroup sales in the low single digit ra...

Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news